Aldurazyme + Aldurazyme + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome
Trial Timeline
May 1, 2001 → Mar 1, 2005
NCT ID
NCT00146770About Aldurazyme + Aldurazyme + placebo
Aldurazyme + Aldurazyme + placebo is a phase 3 stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT00146770. Target conditions include Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00146770 | Phase 3 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I